# **Oncologic Care II Panel**

#### Series Editors:

## Betty J. Dong, Pharm.D., FCCP, FASHP, FAPHA, AAHIVP

Professor of Clinical Pharmacy and Family and Community Medicine University of California Schools of Pharmacy and Medicine San Francisco, California

## David P. Elliott, Pharm.D., FCCP, FASCP, CGP, AGSF

Professor and Associate Chair for the Charleston Division
Department of Clinical Pharmacy
West Virginia University School of Pharmacy
Charleston, West Virginia

## **Faculty Panel Chair:**

## Julianna A. Merten, Pharm.D., BCPS, BCOP

Clinical Pharmacy Specialist – Hematology/Oncology Oncology Pharmacy Assistant Residency Program Director Mayo Clinic

Rochester, Minnesota

# **Toxicities of Targeted Oral Chemotherapy**

#### **Author**

## Lisa K. Lohr, Pharm.D., BCPS, BCOP

Clinical Pharmacy Specialist
Masonic Cancer Clinic
University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota

### Reviewers

#### Robert Mancini, Pharm.D., BCOP

Clinical Oncology Pharmacist; PGY2
Oncology Residency Director
Department of Pharmacy
St. Luke's Mountain States Tumor Institute
Clinical Adjunct Professor
Department of Pharmacy Practice
Idaho State University, College of Pharmacy
Boise, Idaho

#### Tristan Lindfelt, Pharm.D., BCPS, BCOP, BCACP

Editor

Medical Information Epocrates/athenahealth San Francisco, California Associate Professor Department of Clinical Sciences Touro University California Vallejo, California

#### Eva Y. Wong, Pharm.D., BCPS, BCACP, CDE

Assistant Professor
Department of Pharmacy Practice
Marshall B. Ketchum University
Fullerton, California

## Melanoma

#### **Author**

## LeAnn B. Norris, Pharm.D., FCCP, BCPS, BCOP

Clinical Associate Professor

Department of Clinical Pharmacy and Outcomes Sciences
University of South Carolina
Columbia, South Carolina

#### Reviewers

### Chrystia M. Zobniw, Pharm.D., BCPS, BCOP

Clinical Pharmacy Specialist MD Anderson Cancer Center Houston, Texas

## Karen L. Kier, BSPharm, Ph.D., BCPS, BCACP, CTTS

Professor of Clinical Pharmacy
Director of Assessment, Preventive Care Specialist
Department of Pharmacy Practice
Ohio Northern University
Ada, Ohio

## Kimberly N. Flynn, Pharm.D., BCPS

Clinical Pharmacy Specialist
Pharmacy Department
Kentucky One Health-Saint Joseph East
Lexington, Kentucky

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Oncologic Care II chapters:

#### Emilie L. Karpiuk, Pharm.D., BCPS

Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

## Mary Wun-Len Lee, Pharm.D., FCCP, BCPS

Vice President and Chief Academic Officer
Pharmacy and Optometry Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

## **DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

Consultancies: Alexandre Chan (Merck Sharp & Dohme, Mundipharma); Lisa M. Holle (HOPA, Innocrin Pharmaceuticals); Robert Mancini (Taiho Pharmaceuticals); Kristen McCullough (HOPA); Cindy L. O'Bryant (Heron Therapeutics); Kamakshi V. Rao (BPS Oncology Specialty Council); Vivian Tsang (HOPA); Sol Atienza Yoder (HOPA, BPS Oncology Specialty Council)

Stock Ownership: Stephanie Gaston (Fred Meyer)

Royalties: Karen L. Kier (McGraw-Hill Medical Publishing)

Grants: Cindy L. O'Bryant (Astra Zeneca); Kamakshi V. Rao: Grants (University Cancer Research Fund, HOPA Foundation, UNC Gillings School of Global Public Health)

Honoraria: Grace M. Akoh-Arrey (Sanofi Aventis); Alexandre Chan (Merck Sharp & Dohme); Lisa M. Holle (Connecticut Pharmacists Association); Kristen McCullough (Medscape/Web MD); Cindy L. O'Bryant (Amgen); Bobbie Williamson (Northwest AHEC)

#### Other:

Nothing to disclose: Shimaa Elsayed Ahmed; Shubha Bhat; Sara K. Butler; Lisa M. Cordes; Diane M. Erdman; Joanna Ferraro; Kimberly N. Flynn; Monique Giordana; Mary Samy Kelada; Houry Leblebjian; Joyce Y. Lee; Stephanie Su Wen Lim; Tristan Lindfelt; Lisa K. Lohr; Donald C. Moore III; Rita Morelli; Michelle Musser; LeAnn B. Norris; Lisa M. Thompson; Kellie Jones Weddle; Kathryn A. Wheeler; Eva Y. Wong; Chrystia M. Zobniw

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. ACSAP has been approved by BPS for use in BCACP recertification. Information about the BPS recertification process is available online.

Other questions regarding recertification should be directed to:

**Board of Pharmacy Specialties** 

2215 Constitution Avenue NW Washington, DC 20037 (202) 429-7591